The effect of an interleukin receptor antagonist (IL-1ra) on colonocyte eicosanoid release

• Main Authors: G. S. Smith (Author), C. Rieckenberg (Author), W. E. Longo (Author), D. L. Kaminski (Author), J. E. Mazuski (Author), Y. Deshpande (Author), T. A. Miller (Author)
• Format: Book
• Published: Hindawi Limited, 1996-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 0962-9351; 1466-1861; 10.1155/S0962935196000622
• Keywords: Pathology; RB1-214
• Source: Mediators of Inflammation, Vol 5, Iss 6, Pp 449-452 (1996)

We investigated whether an interleukin 1 receptor antagonist (IL-1ra) altered cellular release of prostanoids and leukotrienes in a transformed colonic cell line (CACO-2) in the presence of proinflammatory stimuli. Cellular inflammation was induced by treatment with lipopolysaccharide (LPS) or the cytokine, interleukin 1 beta (IL-1β). In a separate set of experiments, cells were pretreated with IL-1ra prior to exposure to LPS or IL-1β. Prostaglandin E2 and leukotriene B4 (LTB4) levels were quantified by ELISA assays. Both LPS and IL-1β exposure were noted to stimulate cellular PGE2 release, a response which was significantly inhibited by IL-1ra treatment. Either stimulant when administered alone failed to stimulate release of LTB4. When administered after IL-1ra pretreatment however, both stimuli caused a significant increase in LTB4 release. These results suggest that a cytokine receptor antagonist can selectively influence eicosanoid production in this cell line. Furthermore, this study suggests that a IL-1ra may have a future clinical role in the treatment of inflammatory disorders of the colon which are intimately linked to enhanced eicosanoid synthesis.